search for


Original Article
Adverse Factors and the Role of Cisplatin and Vinca Alkaloids for Hearing Impairment in Childhood Cancer Patients and Survivors
Clin Pediatr Hematol Oncol 2017;24:121-9.
Published online October 31, 2017
© 2017 Korean Society of Pediatric Hematology-Oncology and Korean Society for Pediatric Neuro-Oncology

Min Woo Hur, M.D.1,2, Seung Min Hahn, M.D.1,2, In Seok Moon, M.D., Ph.D.3, Ju Yeon Lim, M.D.1,2, Seul Mi Lee, M.D.1,2, Chuhl Joo Lyu, M.D., Ph.D.1,2 and Jung Woo Han, M.D.1,2

1Division of Pediatric Hematology and Oncology, Department of Pediatrics, Yonsei University College of Medicine, Yonsei University Health System, 2Department of Pediatric Hemato-Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, 3Department of Otolaryngology, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea
Correspondence to: Jung Woo Han
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Yonsei University College of Medicine, Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-2228-2060 Fax: +82-2-393-9118 E-mail:
Received September 19, 2017; Revised October 8, 2017; Accepted October 17, 2017.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: Although combined chemotherapy has increased survival rates among children with cancer, such treatments can induce sensorineural hearing loss. Therefore, we aimed to identify risk factors for hearing impairments in patients with childhood cancer. Methods: Audiograms were obtained from 115 patients with childhood cancer and survivors (age <20 years). Pure tone audiometry (PTA) was performed at octave intervals within the range of 250-8000 Hz. We evaluated clinical risk factors associated with hearing impairments. Hearing loss was evaluated based on the maximal decibel (dB) loss in any frequency for each ear (RAmax or LAmax) and weighted mean dB loss for specific frequencies (RAavg or LAavg). Results: Forty percent of patients (N=46) exhibited hearing loss >20 dB based on the weighted mean value in either ear. Severe hearing impairments were observed in 56% of patients with brain tumors. Although cisplatin or vinca alkaloids were significant risk factors for hearing impairment, the use of both cisplatin and vinca alkaloids exhibited the highest odds ratio for hearing impairment (P<0.001, <0.001 for R/LAmax; P=0.099, 0.039 for R/LAavg). Multivariate analysis revealed that the use of both cisplatin and vinca alkaloids was an independent risk factor for hearing impairment based on RAmax, LAmax, and LAavg (P<0.001, <0.001, 0.039, respectively). Conclusion: Our findings indicate that cisplatin and vinca alkaloids exert an additive effect on the risk of hearing impairment in survivors of childhood cancer. Further prospective studies are thus required to determine the most effective chemotherapeutic regimen for reducing ototoxicity.
Keywords: Survivors, Hearing loss, Neoplasms, Cisplatin, Vinca alkaloids
  1. Bhandare N, Jackson A, Eisbruch A, et al. Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys 2010;76:S50-7.
    Pubmed KoreaMed CrossRef
  2. Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics 2010;125:e938-50.
    Pubmed KoreaMed CrossRef
  3. Park HJ, Nam BH, Yun YH, et al. Establishment of Korean childhood cancer survivor cohort and long-term follow-up system. Clin Pediatr Hematol Oncol 2007;14:1-42.
  4. Hirose Y, Simon JA, Ou HC. Hair cell toxicity in anti-cancer drugs: evaluating an anti-cancer drug library for independent and synergistic toxic effects on hair cells using the zebrafish lateral line. J Assoc Res Otolaryngol 2011;12:719-28.
    Pubmed KoreaMed CrossRef
  5. Brinkman TM, Bass JK, Li Z, et al. Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: Results from the St. Jude Lifetime Cohort Study. Cancer 2015;121:4053-61.
    Pubmed KoreaMed CrossRef
  6. Ding D, Allman BL, Salvi R. Review: ototoxic characteristics of platinum antitumor drugs. Anat Rec (Hoboken) 2012;295: 1851-67.
    Pubmed CrossRef
  7. Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013;309:2371-81.
    Pubmed KoreaMed CrossRef
  8. Robison LL, Hudson MM. Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer 2014;14:61-70.
    Pubmed CrossRef
  9. Landier W. Ototoxicity and cancer therapy. Cancer 2016;122: 1647-58.
    Pubmed CrossRef
  10. Mujica-Mota M, Waissbluth S, Daniel SJ. Characteristics of radiation-induced sensorineural hearing loss in head and neck cancer: a systematic review. Head Neck 2013;35:1662-8.
    Pubmed CrossRef
  11. Han JW, Kim HS, Kim BS, et al. Increasing and worsening late effects in childhood cancer survivors during follow-up. J Korean Med Sci 2013;28:755-62.
    Pubmed KoreaMed CrossRef
  12. Han JW, Kwon SY, Won SC, Shin YJ, Ko JH, Lyu CJ. Comprehensive clinical follow-up of late effects in childhood cancer survivors shows the need for early and well-timed intervention. Ann Oncol 2009;20:1170-7.
    Pubmed CrossRef
  13. Stevens G, Flaxman S, Brunskill E, et al. Global and regional hearing impairment prevalence: an analysis of 42 studies in 29 countries. Eur J Public Health 2013;23:146-52.
    Pubmed CrossRef
  14. Yun C, Wang Z, Gao J, et al. Prevalence and social risk factors for hearing impairment in chinese children-a national survey. Int J Environ Res Public Health 2017;14.
  15. Yasui N, Adachi N, Kato M, et al. Cisplatin-induced hearing loss: the need for a long-term evaluating system. J Pediatr Hematol Oncol 2014;36:e241-5.
    Pubmed CrossRef
  16. Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 2010;28:1788-95.
    Pubmed CrossRef
  17. van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev 2016:CD010181.
  18. Lee JW, Pussegoda K, Rassekh SR, et al. Clinical practice recommendations for the management and prevention of cisplatin-induced hearing loss using pharmacogenetic markers. Ther Drug Monit 2016;38:423-31.
    Pubmed CrossRef
  19. Ruggiero A, Trombatore G, Triarico S, et al. Platinum compounds in children with cancer: toxicity and clinical management. Anticancer Drugs 2013;24:1007-19.
    Pubmed CrossRef
  20. Nazir HF, AlFutaisi A, Zacharia M, et al. Vincristine-induced neuropathy in pediatric patients with acute lymphoblastic leukemia in Oman: Frequent autonomic and more severe cranial nerve involvement. Pediatr Blood Cancer 2017;64.
  21. Bass JK, Hua CH, Huang J, et al. Hearing loss in patients who received cranial radiation therapy for childhood cancer. J Clin Oncol 2016;34:1248-55.
    Pubmed KoreaMed CrossRef
  22. Rowe LS, Krauze AV, Ning H, Camphausen KA, Kaushal A. Optimizing the benefit of CNS radiation therapy in the pediatric population-part 1: understanding and managing acute and late toxicities. Oncology (Williston Park) 2017;31:182-8.
  23. Ho GY, Woodward N, Coward JI. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 2016;102:37-46.
    Pubmed CrossRef

October 2018, 25 (2)
Full Text PDF
Send to a friend

Cited By Articles
  • CrossRef (0)

Author ORCID Information
  • Jung Woo Han